Last update
3/19/2026
Reviewed By
Reviewed By
Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 6 Researches
8.7
USERS' SCORE
Good
Based on 2 Reviews
8.3
Supplement Facts
Serving Size: About 1/4 cup (31 g)
Amount Per Serving
%DV
Calories
180
Total Fat
13 g
17%
Saturated Fat
3 g
15%
Trans Fat
0 g
Cholesterol
0 mg
0%
Sodium
0 mg
0%
Total Carbohydrate
4 g
1%
Dietary Fiber
2 g
7%
Total Sugars
0 g
Includes 0g Added Sugars
0%
Protein
11g
Vit. D
0 mcg
0%
Calcium
8 mg
0%
Iron
4 mg
20%
Potassium
243 mg
6%
Top Medical Research Studies
8
We explored how a specific protein, Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), influences the development of bone marrow mesenchymal stem cells (BMSCs) into bone-forming cells, especially in the context of osteoporosis (OP). Our aim was to uncover the molecular mechanisms that contribute to this transformation and possibly identify new treatment routes for OP.
We conducted a series of experiments that included analyzing mRNA expression levels and protein detection through various methods. Through techniques like alkaline phosphatase staining and Alizarin Red staining, we evaluated how well BMSCs differentiated into bone-forming cells. Our findings revealed that KLK4—a protein crucial for bone formation—was underexpressed in OP patients but significantly increased in successfully differentiated BMSCs.
Importantly, we observed that IGF2BP3 enhances the expression of KLK4, thereby promoting the osteogenic differentiation of the BMSCs. When KLK4 levels were increased, they could counteract the negative effects seen when IGF2BP3 was downregulated. These results highlight the significant role IGF2BP3 plays in supporting BMSC development into bone-forming cells, presenting a promising target for osteoporosis treatment.
We conducted a series of experiments that included analyzing mRNA expression levels and protein detection through various methods. Through techniques like alkaline phosphatase staining and Alizarin Red staining, we evaluated how well BMSCs differentiated into bone-forming cells. Our findings revealed that KLK4—a protein crucial for bone formation—was underexpressed in OP patients but significantly increased in successfully differentiated BMSCs.
Importantly, we observed that IGF2BP3 enhances the expression of KLK4, thereby promoting the osteogenic differentiation of the BMSCs. When KLK4 levels were increased, they could counteract the negative effects seen when IGF2BP3 was downregulated. These results highlight the significant role IGF2BP3 plays in supporting BMSC development into bone-forming cells, presenting a promising target for osteoporosis treatment.
Read More
8
We investigated the potential of the Klotho protein, specifically its secreted form (s-KL), in promoting healthy aging and its effects on osteoporosis. By delivering a viral vector that increases s-KL levels in wild-type mice, we observed a significant rise in the protein's concentration in their blood, which led to a commendable 20% increase in lifespan.
Our results showed promising improvements in bone health. Mice treated with s-KL exhibited better bone microstructure, which is crucial in combating osteoporosis. This suggests that increasing s-KL levels could play a role in enhancing bone quality and potentially reducing the risk of age-related bone diseases.
Beyond just bone health, we also found that s-KL treatment had multifaceted benefits, including improved muscle fitness and better immune responses, which could contribute to overall well-being as we age. These exciting findings highlight the potential of s-KL not only in addressing osteoporosis but also in supporting a healthier aging process across multiple systems in the body.
Our results showed promising improvements in bone health. Mice treated with s-KL exhibited better bone microstructure, which is crucial in combating osteoporosis. This suggests that increasing s-KL levels could play a role in enhancing bone quality and potentially reducing the risk of age-related bone diseases.
Beyond just bone health, we also found that s-KL treatment had multifaceted benefits, including improved muscle fitness and better immune responses, which could contribute to overall well-being as we age. These exciting findings highlight the potential of s-KL not only in addressing osteoporosis but also in supporting a healthier aging process across multiple systems in the body.
Read More
9
We investigated the role of human small leucine zipper protein (sLZIP) in bone remodeling, particularly focusing on osteoporosis. Our research revealed that sLZIP has a significant impact on both osteoblasts, which are the cells responsible for bone formation, and osteoclasts, the cells that break down bone.
By studying specially designed mouse models, we found that sLZIP contributes to increased bone mass. Specifically, in a model of osteoporosis, mice lacking sLZIP showed a reduced ability to heal bone fractures and a lower bone mass compared to control mice. This highlights how essential sLZIP is in maintaining bone health.
Moreover, we observed intriguing dynamics between the two cell types. While osteoblasts from the deficient mice failed to support osteoclast formation and migration effectively, osteoclasts from sLZIP-enhanced mice promoted osteoblast activity. This indicates that sLZIP not only regulates its own type of cell but also positively influences other cells within the bone environment, facilitating better bone healing and remodeling.
Overall, our findings suggest that sLZIP is a vital regulator in the crosstalk between bone-forming and bone-resorbing cells. This regulatory role positions sLZIP as a promising target for developing cell-based therapies aimed at treating osteoporosis, potentially enabling better recovery and strengthening of bone structure.
By studying specially designed mouse models, we found that sLZIP contributes to increased bone mass. Specifically, in a model of osteoporosis, mice lacking sLZIP showed a reduced ability to heal bone fractures and a lower bone mass compared to control mice. This highlights how essential sLZIP is in maintaining bone health.
Moreover, we observed intriguing dynamics between the two cell types. While osteoblasts from the deficient mice failed to support osteoclast formation and migration effectively, osteoclasts from sLZIP-enhanced mice promoted osteoblast activity. This indicates that sLZIP not only regulates its own type of cell but also positively influences other cells within the bone environment, facilitating better bone healing and remodeling.
Overall, our findings suggest that sLZIP is a vital regulator in the crosstalk between bone-forming and bone-resorbing cells. This regulatory role positions sLZIP as a promising target for developing cell-based therapies aimed at treating osteoporosis, potentially enabling better recovery and strengthening of bone structure.
Read More
Most Useful Reviews
7.5
Hormonal regulation
Pumpkin seeds can regulate female hormones and help prevent osteoporosis. The natural taste is delightful, allowing you to enjoy the plain flavour without any additives.
Read More
7.5
Prostate health
Pumpkin seeds are reported to control an enlarged prostate and prevent osteoporosis in women, thanks to phytosterols and lignans. Be aware that the price has increased, though you might consider roasting the seeds yourself in the future.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 6 Researches
8.7
- All Researches
9
We investigated how a unique protein complex, derived from Antarctic krill and enriched with pectin, influences calcium absorption and bone health, especially in the context of osteoporosis. Using a calcium-deficient mouse model, we assessed the effects of this complex, known as P + Ca + HMP, on calcium intake and bone structure.
Our findings were impressive: chronic low calcium levels led to reduced calcium absorption and weakened bone architecture. However, the P + Ca + HMP complex turned the situation around. It improved calcium retention significantly and strengthened the femur, showcasing enhanced mechanical properties of the bone.
Additionally, the complex aided in improving the structure of the bone’s trabecular network, making it thicker and more integral. We also noted an increase in beneficial gut bacteria associated with better calcium absorption and bone health after administering the complex.
Overall, the P + Ca + HMP complex demonstrated the potential to effectively deliver calcium, support a healthy gut environment, and promote stronger bones, making it a promising candidate for preventing calcium deficiency.
Our findings were impressive: chronic low calcium levels led to reduced calcium absorption and weakened bone architecture. However, the P + Ca + HMP complex turned the situation around. It improved calcium retention significantly and strengthened the femur, showcasing enhanced mechanical properties of the bone.
Additionally, the complex aided in improving the structure of the bone’s trabecular network, making it thicker and more integral. We also noted an increase in beneficial gut bacteria associated with better calcium absorption and bone health after administering the complex.
Overall, the P + Ca + HMP complex demonstrated the potential to effectively deliver calcium, support a healthy gut environment, and promote stronger bones, making it a promising candidate for preventing calcium deficiency.
Read More
9
We investigated the role of human small leucine zipper protein (sLZIP) in bone remodeling, particularly focusing on osteoporosis. Our research revealed that sLZIP has a significant impact on both osteoblasts, which are the cells responsible for bone formation, and osteoclasts, the cells that break down bone.
By studying specially designed mouse models, we found that sLZIP contributes to increased bone mass. Specifically, in a model of osteoporosis, mice lacking sLZIP showed a reduced ability to heal bone fractures and a lower bone mass compared to control mice. This highlights how essential sLZIP is in maintaining bone health.
Moreover, we observed intriguing dynamics between the two cell types. While osteoblasts from the deficient mice failed to support osteoclast formation and migration effectively, osteoclasts from sLZIP-enhanced mice promoted osteoblast activity. This indicates that sLZIP not only regulates its own type of cell but also positively influences other cells within the bone environment, facilitating better bone healing and remodeling.
Overall, our findings suggest that sLZIP is a vital regulator in the crosstalk between bone-forming and bone-resorbing cells. This regulatory role positions sLZIP as a promising target for developing cell-based therapies aimed at treating osteoporosis, potentially enabling better recovery and strengthening of bone structure.
By studying specially designed mouse models, we found that sLZIP contributes to increased bone mass. Specifically, in a model of osteoporosis, mice lacking sLZIP showed a reduced ability to heal bone fractures and a lower bone mass compared to control mice. This highlights how essential sLZIP is in maintaining bone health.
Moreover, we observed intriguing dynamics between the two cell types. While osteoblasts from the deficient mice failed to support osteoclast formation and migration effectively, osteoclasts from sLZIP-enhanced mice promoted osteoblast activity. This indicates that sLZIP not only regulates its own type of cell but also positively influences other cells within the bone environment, facilitating better bone healing and remodeling.
Overall, our findings suggest that sLZIP is a vital regulator in the crosstalk between bone-forming and bone-resorbing cells. This regulatory role positions sLZIP as a promising target for developing cell-based therapies aimed at treating osteoporosis, potentially enabling better recovery and strengthening of bone structure.
Read More
9
We explored the potential of stigmasterol (STG), a compound sourced from various plants, in treating osteoporosis in rats with type 2 diabetes mellitus (T2DM). This research involved a controlled study with twenty-four male Sprague-Dawley rats, divided into groups receiving different diets and doses of STG for four weeks.
Our findings indicated that STG treatment improved bone density and structure significantly in the diabetic rats. The higher dose, in particular, showed marked improvements compared to those on a high-fat diet. We observed enhanced trabecular bone microstructure, increased levels of bone formation markers like P1NP and osteocalcin, and decreased bone resorption indices.
These results suggest that stigmasterol could serve as a supportive therapy for managing osteoporosis, particularly in the context of diabetes. However, it's essential to recognize that the study does not isolate the impact of protein itself, leaving us with an incomplete understanding of protein's role in the context of stigmasterol treatment.
Our findings indicated that STG treatment improved bone density and structure significantly in the diabetic rats. The higher dose, in particular, showed marked improvements compared to those on a high-fat diet. We observed enhanced trabecular bone microstructure, increased levels of bone formation markers like P1NP and osteocalcin, and decreased bone resorption indices.
These results suggest that stigmasterol could serve as a supportive therapy for managing osteoporosis, particularly in the context of diabetes. However, it's essential to recognize that the study does not isolate the impact of protein itself, leaving us with an incomplete understanding of protein's role in the context of stigmasterol treatment.
Read More
9
We examined the impact of recombinant human parathyroid hormone (rhPTH) alongside electromagnetic field (EMF) therapy on postmenopausal osteoporosis (PMOP). In this study, 336 patients were divided into three groups: one receiving both EMF and rhPTH, another receiving only rhPTH, and a third group receiving just EMF.
Over the course of 18 months, we measured bone mineral density (BMD) in the lumbar spine and femoral neck, as well as various indicators of bone turnover. The results indicated that those in the EMF combined with rhPTH group experienced significant improvements in BMD and bone turnover markers compared to those in the EMF-only group.
Specifically, levels of calcium and bone alkaline phosphatase (BSAP), along with other important markers, increased in both treatment groups, but notably more in the combination therapy. These findings suggest that combining rhPTH with EMF may enhance treatment for PMOP, improving bone density and overall bone health.
Our findings highlight the potential for more effective osteoporosis treatments by integrating innovative therapies like EMF with established protein-based treatments like rhPTH.
Over the course of 18 months, we measured bone mineral density (BMD) in the lumbar spine and femoral neck, as well as various indicators of bone turnover. The results indicated that those in the EMF combined with rhPTH group experienced significant improvements in BMD and bone turnover markers compared to those in the EMF-only group.
Specifically, levels of calcium and bone alkaline phosphatase (BSAP), along with other important markers, increased in both treatment groups, but notably more in the combination therapy. These findings suggest that combining rhPTH with EMF may enhance treatment for PMOP, improving bone density and overall bone health.
Our findings highlight the potential for more effective osteoporosis treatments by integrating innovative therapies like EMF with established protein-based treatments like rhPTH.
Read More
8
We explored how a specific protein, Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), influences the development of bone marrow mesenchymal stem cells (BMSCs) into bone-forming cells, especially in the context of osteoporosis (OP). Our aim was to uncover the molecular mechanisms that contribute to this transformation and possibly identify new treatment routes for OP.
We conducted a series of experiments that included analyzing mRNA expression levels and protein detection through various methods. Through techniques like alkaline phosphatase staining and Alizarin Red staining, we evaluated how well BMSCs differentiated into bone-forming cells. Our findings revealed that KLK4—a protein crucial for bone formation—was underexpressed in OP patients but significantly increased in successfully differentiated BMSCs.
Importantly, we observed that IGF2BP3 enhances the expression of KLK4, thereby promoting the osteogenic differentiation of the BMSCs. When KLK4 levels were increased, they could counteract the negative effects seen when IGF2BP3 was downregulated. These results highlight the significant role IGF2BP3 plays in supporting BMSC development into bone-forming cells, presenting a promising target for osteoporosis treatment.
We conducted a series of experiments that included analyzing mRNA expression levels and protein detection through various methods. Through techniques like alkaline phosphatase staining and Alizarin Red staining, we evaluated how well BMSCs differentiated into bone-forming cells. Our findings revealed that KLK4—a protein crucial for bone formation—was underexpressed in OP patients but significantly increased in successfully differentiated BMSCs.
Importantly, we observed that IGF2BP3 enhances the expression of KLK4, thereby promoting the osteogenic differentiation of the BMSCs. When KLK4 levels were increased, they could counteract the negative effects seen when IGF2BP3 was downregulated. These results highlight the significant role IGF2BP3 plays in supporting BMSC development into bone-forming cells, presenting a promising target for osteoporosis treatment.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Hormonal regulation
Pumpkin seeds can regulate female hormones and help prevent osteoporosis. The natural taste is delightful, allowing you to enjoy the plain flavour without any additives.
Read More
7.5
Prostate health
Pumpkin seeds are reported to control an enlarged prostate and prevent osteoporosis in women, thanks to phytosterols and lignans. Be aware that the price has increased, though you might consider roasting the seeds yourself in the future.
Read More
Frequently Asked Questions
9
We investigated how a unique protein complex, derived from Antarctic krill and enriched with pectin, influences calcium absorption and bone health, especially in the context of osteoporosis. Using a calcium-deficient mouse model, we assessed the effects of this complex, known as P + Ca + HMP, on calcium intake and bone structure.
Our findings were impressive: chronic low calcium levels led to reduced calcium absorption and weakened bone architecture. However, the P + Ca + HMP complex turned the situation around. It improved calcium retention significantly and strengthened the femur, showcasing enhanced mechanical properties of the bone.
Additionally, the complex aided in improving the structure of the bone’s trabecular network, making it thicker and more integral. We also noted an increase in beneficial gut bacteria associated with better calcium absorption and bone health after administering the complex.
Overall, the P + Ca + HMP complex demonstrated the potential to effectively deliver calcium, support a healthy gut environment, and promote stronger bones, making it a promising candidate for preventing calcium deficiency.
Our findings were impressive: chronic low calcium levels led to reduced calcium absorption and weakened bone architecture. However, the P + Ca + HMP complex turned the situation around. It improved calcium retention significantly and strengthened the femur, showcasing enhanced mechanical properties of the bone.
Additionally, the complex aided in improving the structure of the bone’s trabecular network, making it thicker and more integral. We also noted an increase in beneficial gut bacteria associated with better calcium absorption and bone health after administering the complex.
Overall, the P + Ca + HMP complex demonstrated the potential to effectively deliver calcium, support a healthy gut environment, and promote stronger bones, making it a promising candidate for preventing calcium deficiency.
9
We explored the potential of stigmasterol (STG), a compound sourced from various plants, in treating osteoporosis in rats with type 2 diabetes mellitus (T2DM). This research involved a controlled study with twenty-four male Sprague-Dawley rats, divided into groups receiving different diets and doses of STG for four weeks.
Our findings indicated that STG treatment improved bone density and structure significantly in the diabetic rats. The higher dose, in particular, showed marked improvements compared to those on a high-fat diet. We observed enhanced trabecular bone microstructure, increased levels of bone formation markers like P1NP and osteocalcin, and decreased bone resorption indices.
These results suggest that stigmasterol could serve as a supportive therapy for managing osteoporosis, particularly in the context of diabetes. However, it's essential to recognize that the study does not isolate the impact of protein itself, leaving us with an incomplete understanding of protein's role in the context of stigmasterol treatment.
Our findings indicated that STG treatment improved bone density and structure significantly in the diabetic rats. The higher dose, in particular, showed marked improvements compared to those on a high-fat diet. We observed enhanced trabecular bone microstructure, increased levels of bone formation markers like P1NP and osteocalcin, and decreased bone resorption indices.
These results suggest that stigmasterol could serve as a supportive therapy for managing osteoporosis, particularly in the context of diabetes. However, it's essential to recognize that the study does not isolate the impact of protein itself, leaving us with an incomplete understanding of protein's role in the context of stigmasterol treatment.
9
We investigated the role of human small leucine zipper protein (sLZIP) in bone remodeling, particularly focusing on osteoporosis. Our research revealed that sLZIP has a significant impact on both osteoblasts, which are the cells responsible for bone formation, and osteoclasts, the cells that break down bone.
By studying specially designed mouse models, we found that sLZIP contributes to increased bone mass. Specifically, in a model of osteoporosis, mice lacking sLZIP showed a reduced ability to heal bone fractures and a lower bone mass compared to control mice. This highlights how essential sLZIP is in maintaining bone health.
Moreover, we observed intriguing dynamics between the two cell types. While osteoblasts from the deficient mice failed to support osteoclast formation and migration effectively, osteoclasts from sLZIP-enhanced mice promoted osteoblast activity. This indicates that sLZIP not only regulates its own type of cell but also positively influences other cells within the bone environment, facilitating better bone healing and remodeling.
Overall, our findings suggest that sLZIP is a vital regulator in the crosstalk between bone-forming and bone-resorbing cells. This regulatory role positions sLZIP as a promising target for developing cell-based therapies aimed at treating osteoporosis, potentially enabling better recovery and strengthening of bone structure.
By studying specially designed mouse models, we found that sLZIP contributes to increased bone mass. Specifically, in a model of osteoporosis, mice lacking sLZIP showed a reduced ability to heal bone fractures and a lower bone mass compared to control mice. This highlights how essential sLZIP is in maintaining bone health.
Moreover, we observed intriguing dynamics between the two cell types. While osteoblasts from the deficient mice failed to support osteoclast formation and migration effectively, osteoclasts from sLZIP-enhanced mice promoted osteoblast activity. This indicates that sLZIP not only regulates its own type of cell but also positively influences other cells within the bone environment, facilitating better bone healing and remodeling.
Overall, our findings suggest that sLZIP is a vital regulator in the crosstalk between bone-forming and bone-resorbing cells. This regulatory role positions sLZIP as a promising target for developing cell-based therapies aimed at treating osteoporosis, potentially enabling better recovery and strengthening of bone structure.
8
We explored how a specific protein, Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), influences the development of bone marrow mesenchymal stem cells (BMSCs) into bone-forming cells, especially in the context of osteoporosis (OP). Our aim was to uncover the molecular mechanisms that contribute to this transformation and possibly identify new treatment routes for OP.
We conducted a series of experiments that included analyzing mRNA expression levels and protein detection through various methods. Through techniques like alkaline phosphatase staining and Alizarin Red staining, we evaluated how well BMSCs differentiated into bone-forming cells. Our findings revealed that KLK4—a protein crucial for bone formation—was underexpressed in OP patients but significantly increased in successfully differentiated BMSCs.
Importantly, we observed that IGF2BP3 enhances the expression of KLK4, thereby promoting the osteogenic differentiation of the BMSCs. When KLK4 levels were increased, they could counteract the negative effects seen when IGF2BP3 was downregulated. These results highlight the significant role IGF2BP3 plays in supporting BMSC development into bone-forming cells, presenting a promising target for osteoporosis treatment.
We conducted a series of experiments that included analyzing mRNA expression levels and protein detection through various methods. Through techniques like alkaline phosphatase staining and Alizarin Red staining, we evaluated how well BMSCs differentiated into bone-forming cells. Our findings revealed that KLK4—a protein crucial for bone formation—was underexpressed in OP patients but significantly increased in successfully differentiated BMSCs.
Importantly, we observed that IGF2BP3 enhances the expression of KLK4, thereby promoting the osteogenic differentiation of the BMSCs. When KLK4 levels were increased, they could counteract the negative effects seen when IGF2BP3 was downregulated. These results highlight the significant role IGF2BP3 plays in supporting BMSC development into bone-forming cells, presenting a promising target for osteoporosis treatment.
References
- Chen L, Lin S, He X, Ye J, Huang Y, et al. A calcium-loaded complex based on Antarctic krill protein and supplemented with pectin promotes calcium absorption and bone health. Int J Biol Macromol. 2025. 10.1016/j.ijbiomac.2025.141634
- Park S, Kim J, Ko J. sLZIP functions as a key modulator of bone remodeling by regulating the crosstalk between osteoblasts and osteoclasts. Exp Mol Med. 2025. 10.1038/s12276-025-01414-3
- Wang H, Mao Z, Xiang H, Huang H, Yang X, et al. Stigmasterol, a Major Component of , Ameliorates Osteoporosis in Diabetes Mellitus Effects by Increasing Bone Mineral Density. J Musculoskelet Neuronal Interact. 2025;25:142. 10.22540/JMNI-25-142
- Tang J, Zhao G, Zhao J, Wang B. IGF2BP3 facilitates the osteogenic differentiation of bone marrow mesenchyml stem cells via upregulating KLK4. Connect Tissue Res. 2025;66:49. 10.1080/03008207.2025.2458129
- Roig-Soriano J, Edo Á, Verdés S, Martín-Alonso C, Sánchez-de-Diego C, et al. Long-term effects of s-KL treatment in wild-type mice: Enhancing longevity, physical well-being, and neurological resilience. Mol Ther. 2025. 10.1016/j.ymthe.2025.02.030
- Xuan M, Wang B, Bi W, Li Y, Song L, et al. Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field. Aging Clin Exp Res. 2025;37:44. 10.1007/s40520-025-02932-w
Data last updated:
